Drug testing programs are a way for the federal government to catch and correct problems with drugs without the use of costly expensive testing equipment.
But federal prosecutors have criticized the programs for not being cost-effective.
The Justice Department’s Drug Enforcement Administration is the agency that oversees drug testing.
It launched the program last year and began offering it in December.
It now has about 5,500 workers across the country, including nearly 4,000 in Washington state, which started the program in 2010.
But drug testing programs have drawn criticism from some federal prosecutors, including one who testified in a Senate committee hearing on Thursday.
The program’s cost, the Drug Enforcement Agency told the Senate panel, is not cost-competitive with other forms of government testing.
In fact, the program is only half the cost of a traditional drug test, according to the agency’s own budget documents.
The cost of testing is about $10,000 per case, the documents said.
The DEA’s budget is only about $20 million a year, according the budget documents reviewed by The Washington Post.
Drug testing programs also have raised questions about the use and accountability of the government’s drug enforcement system, which is widely seen as overburdened by overzealous drug agents.
In one federal drug-related case, a federal judge in Seattle last year dismissed an appeals court ruling that ruled the federal drug court system could not require drug test results for all drug defendants.
The ruling, in which a Seattle federal judge sided with the state, also found that the court’s failure to require a drug test on the same defendants who could be held in jail was not a violation of the state’s constitutional prohibition against cruel and unusual punishment.
In a separate case, federal judges in Texas and Ohio last year ruled that prosecutors could not demand drug testing on a defendant who was already convicted of a drug offense.
They also said it was a violation under the federal Constitution for a drug court to require the testing of defendants convicted of drug offenses, which the courts interpreted to include those with prior drug offenses.
In his testimony, the DEA inspector general also said the DEA’s testing program “does not meet the standards for efficacy and efficiency” and is not a cost-saving measure.
The Drug Enforcement Administrators Office also said in its budget document that it would not test anyone who had not been convicted of an offense.
But the DEA did not specify how many employees are now required to be tested, and it was unclear how many drug-involved people the agency would test.